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 Abstract 
Objective 
Evaluate the quality and acceptability of patient-reported outcome measures used to assess 
fatigue in patients with Axial Spondyloarthritis.  
Methods 
A two-stage systematic review of major electronic databases (1980-2017) to: 1) Identify 
measures; and 2) Identify evaluative studies. Study and measurement quality was evaluated 
following international standards. Measurement content was appraised against a conceptual 
model of RA-fatigue.  
Results 
From 387 reviewed abstracts, 23 articles provided evidence for nine fatigue-specific measures: 
six multi-item and three single-item. No axSpA-fatigue specific measure was identified. 
Evidence of reliability was limited, but acceptable for the Multi-dimensional Fatigue Inventory 
(internal consistency, test-retest) and Short Form 36-item Health Survey Vitality subscale (SF-36 
VT) (internal consistency). Evidence of construct validity was moderate for the Functional 
Assessment of Chronic Illness Therapy-Fatigue and 10cm visual analogue scale, limited for the 
SF-36 VT, and not available for the remaining measures. Responsiveness was rarely evaluated. 
Evidence of measurement error, content validity or structural validity was not identified.  
Most measures provide a limited reflection of fatigue; the most comprehensive were the Multi-
dimensional Assessment of Fatigue (MAF), MFI-20, FACIT-fatigue and Fatigue Severity Scale 
(FSS).  
Conclusion 
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 The limited content and often poor quality of the reviewed measures limits any clear 
recommendation for fatigue-assessment in this population; assessments should be applied with 
caution until further robust evidence is established. Well developed, patient-derived measures 
can provide essential evidence of the patient’s perspective to inform clinical research and drive 
tailored healthcare. The collaborative engagement of key stakeholders must seek to ensure that 
future fatigue assessment is relevant, acceptable and of high quality.  
 
Keywords: fatigue assessment; measurement quality; acceptability; axial spondyloarthritis; 
systematic review 
 
Key messages:  
1) Fatigue is important to patients, but the quality and acceptability of assessment is limited. 
2) Fatigue assessment is limited by methodological quality and limited relevance to patients. 
3) Future guidance should be co-produced with patients, ensuring both assessment relevance 
and methodological rigor. 
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 Introduction 
Pain, stiffness, reduced mobility and fatigue are cardinal features of axial spondyloarthritis 
(axSpA), including Ankylosing Spondylitis (AS). (1). However, despite the importance afforded 
to fatigue by patients (2, 3), fatigue severity was only added to international assessment guidance 
for axSpA in 2009 (4). Accordingly, fatigue assessment in axSpA clinical trials increased 
significantly from just 17.1% of trials completed pre-2001 to 84% post-2001 (5), with most trials 
(84%) using the single fatigue-severity visual analogue scale (VAS) recommended in the 
assessment guidance (6).  A recent conceptualisation of fatigue in rheumatoid arthritis (RA) 
demonstrated the multi-faceted and often-complex relationships between disease-specific, 
cognitive/ behavioural (behaviour, cognitive, emotion) and personal (support, health, 
environment, responsibilities) factors (7) – a complexity that might not be readily captured with 
a single item of severity (8). Moreover, individuals experiencing significant impairment due to 
frequent, but not severe (VAS scores <5), fatigue would not be identified if assessment were 
informed purely by fatigue severity (8). Patients’ fatigue experience may, therefore, be better 
captured with multi-item, multi-domain patient-reported outcome measures (PROMs), providing 
a structured, patient-reported assessment of health (9, 10). These may be generic – containing 
items reflecting general health and completed by any population – or specific – to a condition 
(e.g., axSpA), an aspect of health (e.g., fatigue), or a population (e.g., children). A scoping 
review of fatigue measures used in rheumatology listed more than twelve multi-item measures, 
but just one rheumatology-specific, multi-item measure (11) - the Bristol RA Fatigue Multi-
Dimensional Questionnaire (BRAF-MDQ) (12, 13). However, the quality, acceptability and 
relevance of measures was not explored, thus limiting evidence-based recommendations.  
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 This review will systematically appraise, compare and synthesise published evidence of the 
quality and acceptability of clearly defined single and multi-item PROMs used in fatigue 
assessment in axSpA to establish the quality and acceptability of fatigue measures. The review 
will provide a transparent assessment of the evidence with which to inform PROM selection for 
future application in axSpA research and clinical practice.   
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 Method 
Identification of studies and PROMs 
Medical Subject Headings (MeSH) and free text searching reflected: 1) population – axSpA/AS; 
2) construct – fatigue; 3) assessment type – PROMs; and 4) measurement and practical 
properties (14). Five databases were searched: MEDLINE (OVID), EMBASE (OVID), 
PsycINFO (OVID), CINAHL and Web of Science; January 1980 to August 2017. A second 
search used the names of identified measures: 1) population; 2) construct; 3) named measures; 
and 4) measurement properties. Reference lists of included studies and existing reviews were 
reviewed (11, 15). 
 
Eligibility criteria 
One author (NAP) assessed all titles and abstracts; agreement was independently checked on a 
10% subset by a second author (KLH). A third author (JCP) doubled-assessed all abstracts 
relating to Psoriatic Arthritis. Any conflicts were resolved through discussion. 
 
Study inclusion  
Studies were included if they contained a clearly identifiable and reproducible patient-reported 
assessment of fatigue, reported evidence of development and/or evaluation following completion 
by axSpA patients, and were written in English. Studies were excluded if they were only 
available as abstracts, fatigue assessment was not patient-reported, clearly identifiable or 
reproducible, or the study described PROM application only. 
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 PROM inclusion 
PROMs were included if they were fatigue-specific, assessed fatigue as a separate domain within 
a multi-domain measure, or were single or multi-item assessments. Clinician-reported 
assessments were excluded.  
 
Data extraction and appraisal  
Data extraction was informed by earlier published reviews (16-19), and the COnsensus-based 
Standards for the selection of health status Measurement INstruments (COSMIN) checklist (20-
22). Study and PROM-specific information was extracted. Evidence of measurement properties 
included: validity, reliability, responsiveness, and interpretability (Appendix 2). Practical 
properties included evidence of: feasibility (administration time; scoring) and acceptability 
(patient relevance). Evidence of fatigue-conceptualisation and information pertaining to patient 
involvement was extracted and recorded. The RA-fatigue conceptual model (7) informed a 
comparative appraisal of PROM item content. One reviewer (NAP) completed all data 
extraction. A 10% subset was independently double-extracted (KLH) and agreement checked.  
 
Assessment of study methodological quality 
The COSMIN 4-point checklist informed an assessment of study methodological quality for each 
reported measurement property: “poor”, “fair”, “good” or “excellent” (20-22). The lowest item 
rating per measurement property informed the overall score.  
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 Assessment of PROM quality  
A synthesis of recommendations described by others (18, 19, 23) facilitated the transparent 
appraisal of PROM quality. Measurement properties were appraised and rated accordingly: 
adequate (+); inadequate (-); conflicting (+/-) or unclear (?). (Appendix 2)  
 
Data synthesis and PROM recommendation 
Four factors informed the synthesis: 1) study methodological quality (COSMIN); 2) number of 
studies reporting evidence; 3) ratings for measurement/practical properties per measure; and 4) 
consistency of results between studies (16, 18). The final synthesis, and hence evidence upon 
which PROM recommendation will be made, reflects both: 1) the quality of each measurement 
property: adequate (+), not adequate (-), conflicting (+/-), or unclear (?) (Appendix 2); and 2) 
overall level of evidence for each measurement property: ‘strong – consistent findings in 
multiple studies of good methodological quality OR in one study of excellent quality’, ‘moderate 
- consistent findings in multiple studies of fair methodological quality OR in one study of good 
quality’’, ‘limited – one study of fair methodological quality’, ‘conflicting – conflicting 
findings’, or ‘unknown – only studies of poor methodological quality’ (18).  
PROM recommendations will consider: 1) the extent to which key domains of fatigue identified 
in the RA-fatigue model are reflected the PROM (content validity); 2) whether there is adequate 
evidence, minimally, of measurement validity (structural and construct) and reliability (internal 
consistency and test-retest); and 3) an evidence base that is judged, as a minimum, to be 
moderate. 
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 Results 
Identification of studies and PROMs 
A PRISMA flowchart summarises the review process (Figure 1). Twenty-three articles provided 
evidence for nine fatigue-specific PROMs (Table 1): three multi-dimensional - Multi-
dimensional Assessment of Fatigue (MAF) (24); Multi-dimensional Fatigue Inventory (MFI-20) 
(25); Multi-dimensional Fatigue Symptom Inventory – Short Form (MFSI-SF) (26); three uni-
dimensional  - Functional Assessment of Chronic Illness Therapy (Fatigue) (FACIT-fatigue) 
(27), Fatigue Severity Scale (FSS) (28) and the vitality subscale (VT) of the Short-Form 36-item 
Health Status Survey (SF-36) (29); and three single-item questions: Worst-Fatigue Numeric 
Rating Scale (WF-NRS) (BFI) (30); the 10cm fatigue severity VAS (from the Bath AS Disease 
Activity Index (BASDAI)) (31); and a modified 10cm VAS whereby the descriptor ‘none’ was 
changed to ‘no problem’ (32).  
 
Study and sample characteristics (Appendix 3) 
All studies included adults with a primary diagnosis of axSpA, aged between 18 and 72 years 
old. Sample sizes ranged from 40 to 812.  Studies were predominantly cross-sectional, 
investigating fatigue prevalence and/or its association with other variables.  
 
Measurement properties and methodological quality 
Study methodological quality (per PROM) was assessed and recorded (Appendix 4). An 
evidence synthesis is presented in Table 2. Evidence of measurement error, content or structural 
validity, criterion-based responsiveness, acceptability or feasibility of completion was not 
identified. 
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 Fatigue conceptualisation (Table 1) and Patient Involvement  
A review of PROM development suggests very limited conceptualisation of fatigue for four 
PROMs (MFI-20, MFSI-SF, SF-36 and BFI). Item generation or selection was often poorly 
reported and lacking in transparency. Only the single-item VAS of fatigue severity (taken from 
the BASDAI) was developed specifically for use with axSpA patients; but a conceptualisation of 
fatigue is absent. The involvement of patients did not extend beyond participation (that is, simply 
measurement completion); no study included patients as research partners in measurement 
evaluation.  
 
Comparative item-content  
Whilst similarities of item content exist, all reviewed measures provided a limited reflection of 
the RA-fatigue model (Table 3). All single-item measures assessed fatigue severity. 
 
Multidimensional fatigue-specific PROMs 
Multidimensional Assessment of Fatigue (MAF) (24) 
Six poor quality studies provided limited evidence of construct validity (correlations and known-
groups validity); including small to moderate associations between the MAF total and AS-
specific Bath measures (range 0.23-0.73); and the MAF subscales and SF-36 VT (range 0.3-0.53) 
and 10cm fatigue-severity VAS (range 0.39-0.53) (33-38); all evaluations lacked a priori 
hypothesised associations.  
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 Multidimensional Fatigue Inventory (MFI-20) (25) 
One poor quality study provided limited evidence of construct validity (40). A fair quality study 
provided acceptable evidence of internal consistency (Cronbach’s alpha from 0.68 (Reduced 
Motivation (RM) subscale) to 0.86 (Reduced Activity (RA) subscale)) and construct validity (39) 
(moderate to strong associations between subscales (General Fatigue (GF) with Physical Fatigue 
(PF) 0.69 / RA 0.52 / RM 0.45 / Mental Fatigue (MF) 0.45; MF with PF 0.40 / RA 0.42 / RM 
0.48; RM with PF 0.51 / RA 0.54) supporting assumed a priori hypothesis associations) (39). 
Limited evidence for 1-week test-retest reliability was also reported for patients following 
completion of a VAS on a person’s overall perceived health, taken from the EuroQoL (EQ-5D) 
(ICC range: PF 0.57 to 0.75 RM / MF) in a study judged to be of fair quality (40); for three 
subscales (GF, PF and RA) values less than 0.70 were reported. Distribution-based measures of 
responsiveness – both Effect Size (ES) statistics and the Standardised Response Mean (SRM) - 
were calculated from trial data, without any a priori hypotheses, following 3-month completion 
after the end of spa therapy: small values (<0.3) for domains reflecting reduced activity to large 
(>0.82) for domains reflecting general fatigue and physical fatigue were reported (ES: GF 0.82 / 
PF 0.81 / RA 0.28 / RM 0.54 / MF 0.38), SRM (GF 0.70 / PF 0.82 / RA 0.23 / RM 0.51 / MF 
0.49; Guyatt statistics GF 0.86 / PF 0.96 / RA 0.30 / RM 0.50 / MF 0.57).  
 
Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF) (26) 
One poor quality study provided limited evidence of construct validity (41). Weak to strong 
associations between the MFSI-SF subscales and the BASDAI 10cm VAS were reported (10cm 
VAS with General Fatigue (GF) 0.71 / Physical Fatigue (PF) 0.74 / Emotional Fatigue (EF) 0.56 
/ Mental Fatigue (MF) 0.45 / Vigor -0.32) following completion by 62 AS patients. Whilst 
Downloaded from https://academic.oup.com/rheumap/advance-article-abstract/doi/10.1093/rap/rky017/5025120
by University of Warwick user
on 11 June 2018
 association between variables could be assumed, a priori hypothesised associations were not 
stated.  
 
Unidimensional fatigue PROMs 
Functional Assessment of Chronic Illness Therapy (Fatigue) (FACIT-fatigue) (27) 
One poor quality study provided acceptable evidence of internal consistency (Cronbach’s alpha 
0.82/ 0.86), item-level performance (corrected Item-total correlation (ITC): 0.56 / 0.88) and 
construct validity (42). Good quality evidence of construct validity was available from the same 
article. Strong associations were reported between the FACIT-fatigue and SF-36 VT (range r= 
0.74 to 0.82) and the 10cm VAS (r=-0.69), with moderate associations with the BASDAI index 
score (r=-0.47) and Bath AS Functional Index (BASFI) (r=-0.56) (42). These findings confirmed 
a priori hypothesised associations between variables.  
 
Fatigue Severity Scale (FSS) (28) 
Both strong (0.77) (44) and moderate (0.53) (45) associations between the FFS and the 10cm 
fatigue-severity VAS have been reported in two studies judged to be of poor quality. Small effect 
sizes (ES) were reported at 28-days for participants in both arms of a placebo-controlled trial of 
subcutaneous etanercept (ES 0.15 / -0.23; SRM 0.22 / 0.22) (46).   
 
Short Form Health Survey (SF-36) vitality subscale (VT) (29) 
One fair quality study provided acceptable evidence of construct validity (42): a strong 
association between the VT subscale and the FACIT-fatigue was reported (r=0.74; r=0.82), a 
moderate association with the 10cm VAS (r=-0.49), and a weak association with the BASFI (r=-
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 0.33). One good quality study provided acceptable evidence of internal consistency and item-
level performance (Cronbach’s alpha 0.78/ 0.88; ITC 0.57/ 0.64) (42). Moderate to large ES 
statistics were reported at both 28-days (ES 0.54; SRM 0.83), and 112 days (ES 0.69; SRM 0.75) 
in patients receiving 25mg of etanercept subcutaneously, twice weekly (46).  
 
Single-item fatigue PROMs 
10cm Fatigue-Severity VAS (31) 
One good quality study provided acceptable evidence of construct validity (42). A strong 
association between the item and the FACIT-fatigue (r= -0.69), and a moderate association with 
the SF-36 VT (r=-0.49) was reported following completion by AS patients participating in a 
double-blind, placebo-controlled clinical trial – supporting a priori hypothesised associations.   
A level of test-retest reliability judged to be below accepted standards for group analysis (ICC 
0.60) was reported following a 6-week test-retest period in patients defined as stable on the 
EuroQoL EQ-VAS (general health); the study was judged to be of fair quality (40). However, 
estimates for test-retest reliability are below accepted thresholds for use with groups (0.70) or 
individuals (0.90) (54). In comparison to participants who received placebo or NSAIDs (small 
ES -0.35) (47), large effect size statistics (ES 0.89; SRM 0.89; Guyatt statistics 0.92) were 
reported at 6-weeks for participants receiving the active, spa therapy intervention (40).  
 
Modified 10cm VAS (32) 
The 10cm fatigue-severity VAS descriptor ‘none’ was modified to ‘no problem’ – changing the 
response scale. One poor quality study provided a limited, poor quality interpretative guidance 
(32).  
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 Brief Fatigue Inventory (BFI) – Worst Fatigue Numeric Rating Scale (WF-NRS) (30) 
One qualitative study explored the relevance and acceptability of the WF-NRS single item taken 
from the BFI (55). Although the item was judged to be relevant, the phraseology was confusing 
(‘what best describes your worst fatigue’). A longer recall period than 24-hours was also 
recommended – to better express fatigue variability.  
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 Discussion 
Greater understanding of the impact of fatigue has been identified as a priority by axSpA patients 
(3). However, current assessment guidance is limited to a single-item measure of fatigue severity 
(4), which underestimates the often profound and wide-ranging impact of fatigue on an 
individual’s life. Of the nine reviewed measures, just three were multi-dimensional, containing 
items reflecting different aspects of fatigue. However, no measure was specific to the experience 
of axSpA-fatigue and none had been evaluated for their relevance to axSpA patients. There was 
limited and often poor-quality evidence of reliability and construct validity; and an absence of 
interpretative guidance and evidence of measurement error, content validity or structural validity 
for any of the reviewed measures. Evidence of responsiveness was limited to the reporting of 
effective size statistics, which fail to provide an accurate evaluation of a measures ability to 
detect meaningful change in health (19). Consequently, the lack of minimal measurement 
evidence for validity and reliability means it is not possible to make any assessment 
recommendations.  
This is the first review of the quality and acceptability of measures of fatigue following 
completion by patients with axSpA. The results are strengthened by an evaluation of both study 
(20, 21) and PROM quality (16, 18, 19, 23); paired with a detailed comparative appraisal of 
item-content. However, much of the extracted data came from studies where PROM evaluation 
was not the primary focus on the study. As such, the rigour of the COSMIN criteria meant that 
these studies typically scored poorly. Although a single reviewer (NAP) assessed all titles and 
abstract for review eligibility, a sub-set of titles and abstracts were reviewed by a second 
reviewer (KLH) and reliability checked.   
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 Adoption of the RA-fatigue conceptual model in the current review highlighted the limited 
content validity of the reviewed measures: no PROM fully reflects the RA-model of fatigue. 
Both the MAF and FSS include the assessment of fatigue frequency and severity, two important 
components of the fatigue experience for axSpA patients (8). However, only two PROMs – the 
MFI-20 (10/20 (total) items) and FACIT-fatigue (6/13 items) – include items which seek to 
assess the cognitive/ behavioural (and emotional) impact of fatigue. Other PROMs (MAF, MFSI-
SF, FSS) include items limited to only two of the cognitive/ behavioural domains. Whilst 
adequate evidence of internal consistency and reliability were reported for the MFI-20, it is 
unclear whether the PROM can detect change, or if it measures components of fatigue important 
to axSpA patients. Acceptable, but limited, evidence of a strong association between the FACIT-
fatigue and SF-36 VT, enhances confidence in the ability of the FACIT-fatigue to measure 
fatigue in this population. However, evidence of measurement reliability and responsiveness is 
lacking in the axSpA population. Consequently, whilst demonstrating acceptable item content, 
both measures lack acceptable evidence of essential psychometric properties to currently support 
their use in axSpA-fatigue assessment. A robust fatigue assessment is necessary to detect and 
detail the nuances of fatigue experience that are essential to providing individualised and tailored 
healthcare to axSpA patients. 
Qualitative research has detailed a similar experience of fatigue in axSpA, highlighting the 
significant impact of fatigue on social life patient mental health and relationships with others, 
their ability to engage with usual activities of daily living (56), and their reliance on self-
management strategies (2). This demonstrates the importance of considering these aspects in the 
assessment of fatigue impact, and the insufficient information available from using only a single-
item VAS of fatigue severity (56).  Similarities between RA and axSpA-fatigue experience 
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 supports the appropriateness of the RA-fatigue model as a framework against which PROM 
content and relevance can be appraised for use with the axSpA population (56, 57). However, 
growing evidence demonstrates that fatigue experience is a dynamic, complex and multifaceted 
experience that is, to a large extent, disease-specific . For example, evidence has shown both 
similarities and differences in fatigue experience between related and unrelated conditions 
(fibromyalgia, multiple sclerosis, AS, stroke) (58) and between different stages of illness, too – 
such as patients with active cancer compared to cancer survivors (59). Therefore, whilst this 
review has used the RA-fatigue model to appraise PROM item content, it is essential that a 
conceptual model is developed to reflect the nuances specific to the experience and impact of 
axSpA-fatigue.  
 A review of the quality of fatigue measures used in a range of chronic illnesses also highlighted 
the lack of evidence of essential measurement properties, thus limiting recommendations (61). 
However, the judgement of measurement quality lacked transparency and study methodological 
quality was not determined. International guidance promotes the importance of greater 
transparency in the assessment of measurement quality and acceptability (19, 23, 62). Adoption 
of the COSMIN checklist as per the current review, facilitates the incorporation of study 
methodological quality in the final judgement of PROM quality (20-22).  
Well-developed, patient-derived PROMs are both robust and relevant to the experience of 
patients - capturing the outcomes that really matter (10, 63). However, numerous ‘legacy’ 
measures, where content was largely driven by the perspective of clinicians, may lack relevance 
to patients (10, 63). The failure of PROMs to capture the outcomes that really matter to patients 
(9, 64-66), undermines the potential contribution to patient-centred care and shared decision-
making, and was the driver for the co-development of a new, patient-derived measure of fatigue 
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 for RA – the Bristol RA Fatigue – Multi-dimensional Questionnaire (BRAF-MDQ) (12, 13). Of 
the 9 PROMs identified in this review, only four provided a limited conceptualisation of fatigue, 
which was mostly derived from literature reviews and clinical experts. Only one PROM (FACIT-
Fatigue) was developed following a qualitative method – semi-structured interviews – but did 
not provide a conceptualisation of fatigue. Qualitative research offers greater insight into key 
health issues affecting patients, improving the relevance and acceptability of PROM content. 
This can highlight the unmet needs of patients, supporting targeted healthcare efforts to address 
what really matters to the patient.  
The MFI-20 and FACIT-fatigue provide the most comprehensive assessment of fatigue (7), but 
evidence of their psychometric qualities in the axSpA population is limited.  
A limited number of fatigue-specific PROMs have been evaluated for their quality and 
acceptability for use in axSpA fatigue assessment. However, recommendations are limited by the 
poor methodological quality of most studies coupled with the limited evidence of robust 
measurement or practical properties. These limitations also suggest that data generated from the 
application of these measures in routine practice or clinical research settings should be 
interpreted with caution.  A comparative appraisal of PROM content suggests that the MFI and 
FACIT-fatigue provide the most comprehensive assessment of fatigue, including the impact on 
both cognition and behaviour. However, further exploration of the relevance and acceptability of 
the reviewed measures to patients with axSpA-fatigue is warranted. Moreover, comparative 
evaluations of those measures that have acceptable content validity, are urgently required to 
establish robust evidence essential measurement properties – specifically, reliability, validity, 
responsiveness and interpretation. 
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Figure 1: PRISMA flow-chart of study inclusion 
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Table 1: Summary of the reviewed single- and multi-item fatigue PROMs (n=9). 
PROM 
 
First author (year) 
Completion format 
Completion time 
Conceptual focus 
Response options; Recall period 
How to score 
Multi-dimensional fatigue measures (3/9) 
Multi-dimensional Assessment of Fatigue 
 
(MAF) 
 
Tack (1991) (24) 
 
Completion format: self-completed 
 
Completion time: approx.. <10 mins. 
 
 
 
 
 
 
 
 
 
 
A revision of the Piper Fatigue Scale (PFS) which was developed and tested with oncology patients which was 
designed to measure: temporal, severity and sensory fatigue dimensions. The 41-item PFS was reduced to form the 
16-item MAF. The MAF was developed to measure 4 dimensions: fatigue severity, distress, impact and timing. No 
information provided about item selection, retention or generation. No evidence of patient involvement as research 
partners. MAF developed to measure multiple dimensions of fatigue in adult rheumatoid arthritis patients. 
 
15 questions which contribute to a global fatigue index (GFI). A 16th question does not contribute to the GFI. 4 
subscales explored: distress, severity, interference in daily living activities and frequency/change during the last 
week. 
 
Response options 
NRS from 1-10. Anchors vary by items.  
Items 1 and 4-14 are anchored with “not at all” and “a great deal”.  
Item 2 is anchored with “mild” and “severe”. 
Item 3 is anchored with “no distress” and “a great deal of distress”. 
Items 15 and 16 require an ordinal response with 4 options scored 1-4. 
Item 15 is anchored with “hardly any days” to “every day”. 
Item 16 is anchored with “decreased” to “increased”. 
 
Recall period 
One week 
 
If item 1 is scored as 0 then the remaining items should 
be scored as 0. 
 
Calculating the GFI should be done using the following 
four steps: 
i) sum items 1-3 
ii) average items 4-14 (do not include activities marked 
as “do not do” in the average). 
iii) multiple item 15 by 2.5 to create a score from 0-10. 
iv) sum the values from i, ii and iii together to get a GFI. 
 
Item 16 does not contribute to the GFI but is scored from 
1-4.  
Multi-dimensional Fatigue Inventory 
 
(MFI-20) 
 
Smets (1995) (25) 
 
Completion format: self-completed 
 
Completion time: approx.. 5 mins. 
 
 
 
 
Developed to measure fatigue in cancer patients without somatic items. Initial development was informed by the 
authors and previous research, resulting in 5 proposed domains: general, physical sensations and cognitive 
symptoms which were theoretically supported for inclusion in the MFI based on factor analyses conducted in other 
fatigue studies.  Reduced motivation and reduced activity formed the final 2 components, but unclear whether 
reduced activity was considered a consequence of fatigue. No information about the process of item generation. 
Patients were included as participants but not research partners.  Initially evaluated in patients with cancer, chronic 
fatigue syndrome and healthy individuals whom may experience physical fatigue (military personnel) or mental 
fatigue (newly qualified doctors). 
 
5 subscales, each made up of 4 items (total = 20 items). Half of the items are positively phrased, thus requiring 
reverse scoring. The following 5 subscales were explored: general fatigue, physical fatigue, reduced activity, 
reduced motivation and mental fatigue.  
 
Response options 
A total of 5 check boxes with anchors “yes that is true” to “no that is not true”. 
 
Recall period 
No specific timescale stated. Instructions state “… how you have been feeling lately…” 
 
Each item is scored from 1-5. Positively phrased 
questions (n=10) must be reverse scored.  
 
Subscales can be individually scored by summing their 
respective items. 
Multi-dimensional Fatigue Symptom Inventory – 
Short Form 
 
(MFSI-SF) 
 
MFSI-SF is derived from the MFSI – an 83-item measure informed by evidence from fatigue literature, discussions 
with experts who treat fatigue patients and a review of ‘current’ fatigue measures. Subscales were empirically 
derived from factor analysis. 5 domains were identified: 1) global fatigue experience; 2) somatic symptoms; 3) 
cognitive symptoms; 4) affective symptoms; and 5) behavioural symptoms. Patients were included as participants 
but not as research partners. The MFSI-SF is made up of the empirically derived subscales only. Developed for use 
Total score is a summation of 4 subscales (general + 
physical + emotional + mental) minus vigour. 
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Stein (2004) (26) 
 
Completion format: self-completed 
 
Completion time: approx.. 5 mins. 
 
in cancer patients.  
 
5 subscales, each made up of 6 items (total = 30 items). The 5 subscales explore: general fatigue, physical fatigue, 
emotional fatigue, mental fatigue and vigour. 
 
Response options 
5 response options ranging from 0-4 with anchors “not at all” to “extremely”. 
 
Recall period 
Past 7 days 
 
Uni-dimensional fatigue measures (2/9) 
Functional Assessment Chronic Illness Therapy 
 
(FACIT-fatigue) 
 
Yellen (1997) (27) 
 
Completion format: self-completed 
 
Completion time: approx.. <5 mins. 
 
FACIT-fatigue was developed to measure cancer-related fatigue. Development was two phase: phase 1 (item 
generation) used semi-structured interviews with cancer patients and medical experts; phase 2 (item reduction) was 
a presentation of questions to a second group of medical experts and their review. No conceptual model of fatigue 
was reported,. Patients were included as participants but not research partners. Initial psychometric evaluation (with 
cancer patients) indicates that the measure has good validity and reliability. 
 
Measure is made up of 13 items which ask about fatigue, and how it impacts on daily activities. 
 
Response options 
5 response options with anchors “not at all” to “very much”. 
 
Recall period 
Past 7 days 
 
Global score calculated by summing item scores. 
Fatigue Severity Scale 
 
(FSS) 
 
Krupp (1989) (28) 
 
Completion format: self-completed 
 
Completion time: approx.. <5 mins. 
 
Developed to assess fatigue in patients with multiple sclerosis and systematic lupus erythematosus. Initial 28-item 
fatigue questionnaire was reduced based on the results of a factor analysis, item analysis and theoretical 
considerations – unclear what these considerations were. Five judges sorted items, without labels, into domains. No 
conceptual model of fatigue was reported. Patients were included in the study as research participants only, and not 
as research partners.  
 
Measure made up of 9 items and an additional ‘global fatigue’ VAS. 
 
Response options 
7 response options ranging from 1-7 with anchors “strongly disagree” to “strongly agree”. 
 
Recall period 
Past week 
 
Global score calculated by summing item scores and then 
averaging. 
Single-item fatigue measures (3/9) 
Brief Fatigue Inventory 
 
(BFI) 
 
Worst Fatigue Numeric Rating Scale 
 
(WF-NRS) 
 
Mendoza (1999) (30) 
 
Completion format: self-completed 
 
The BFI was developed to assess fatigue in cancer patients and the impact over the past day. The BFI was based on 
the Brief Pain Inventory (BPI). Questionnaire items were modified following revision of “a fatigue questionnaire” 
completed by cancer patients and healthy controls in a previous study. Partial conceptualisation was provided in the 
explanation of item revision – but the information was limited. Questions seek to investigate: fatigue severity, 
interference with function; factors that worsen fatigue; and contributing factors to fatigue. It consists of ten items 
across two subscales: Fatigue Severity (4 items); and Fatigue Impact (6 items). Patients were involved as 
participants but there was no evidence reported that they were involved as research partners. 
 
The WF-NRS is a single-item on fatigue severity. 
 
Response options 
WF-NRS (item 3) ranges from 0-10 with anchors ranging from “no fatigue” to “as bad as you can imagine”. 
Score taken from the value marked on the VAS. 
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Completion time: approx.. <2 mins. 
 
 
Recall period 
Past 24 hours 
Bath AS Disease Activity Index 
 
(BASDAI) 
 
10cm VAS 
 
Garrett (1994) (31) 
 
Completion format: self-completed 
 
Completion time: approx.. <2 mins. 
 
The BASDAI is an AS-specific measure of disease activity. Development was driven by a team of physiotherapists, 
research associates and rheumatologists. Patients were used as participants to complete a pilot version of the 
questionnaire, but not as research partners. No conceptual model of fatigue was reported. The six items assess pain 
(severity), fatigue/tiredness (severity), stiffness (duration and severity) and tenderness (severity).  
 
Response options 
10cm visual analogue scale with anchors “none” and “very severe” at either end of the scale. 
 
Recall period 
1 week 
Score taken from the value marked on the VAS. 
Modified 10cm VAS 
 
Wheaton (2010) (32) 
 
Completion format: self-completed 
 
Completion time: approx.. <2 mins. 
 
See BASDAI 10cm VAS 
 
Response options 
10cm visual analogue scale with anchors “no problem” and “very severe” at either end of the scale. 
 
Recall period 
Not specified – assumed 1 week (as per original BASDAI single-item on fatigue severity). 
Score taken from the value marked on the VAS. 
Fatigue-specific PROM subscale (1/9) 
Short Form 36-item Health Survey 
(SF-36) 
 
SF-36 vitality subscale 
 
Ware (1992) (29) 
 
Completion format: self-completed 
 
Completion time: approx.. <5 mins. 
 
The SF-36 is a generic measure of health status, containing 36-items across eight health domains: physical 
functioning, role limitations due to physical health or emotional problems, energy, pain, emotional wellbeing, social 
role functioning and general health. Most of the items included were taken from established measures. The content 
of these were reviewed with a view to assign the content to the pre-defined domains – these were informed by data 
from a previous iteration of the short form health survey (SF-20). Patients were not involved as research partners in 
the development process.  
 
Vitality subscale made up of 4 items (2 positively, 2 negatively phrased). 
 
Response options 
6 response options with anchors “none of the time” and “all of the time”. 
 
Recall period 
Last 4 weeks 
 
Positively phrased questions must be reverse scored. 
Scores then summed for all 4 items. 
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Table 2: Data synthesis a, levels of evidence and overall quality b of reviewed PROMs (n=9) 
 
 
Footnote:  
a Data synthesis: Qualitative synthesis of the data determined the quality and acceptability of each reviewed PROM. The synthesis considered four factors:  
1) Study methodological quality (COSMIN scores) 
2) Number of studies reporting evidence of measurement properties (per PROM) 
3) Results for each measurement property (per PROM) 
4) Consistency of results between studies.  
 
The results of data synthesis include two ratings: 
1) Overall measurement property quality: adequate (+), not adequate (-), conflicting (+/-), or unclear (?).  
2) Levels of evidence for the overall quality per measurement property. Five outcomes were defined:  
‘strong’ – consistent findings in multiple studies of good methodological quality OR in one study of excellent quality; ‘moderate’ – consistent findings in multiple studies of fair methodological quality OR in one study of 
good methodological quality; ‘limited’ – one study of fair methodological quality; ‘conflicting’ – conflicting findings; or ‘unknown’ evidence – only studies of poor methodological quality (18, 23). 
PROM / Study 
Number of 
evaluations 
Reliability Construct Validity Responsiveness Interpretation 
Internal consistency Reliability Hypothesis testing Known-groups Responsiveness Other  
Multidimensional fatigue measures (3/9) 
MAF 7    
? 
Unknown 
   
MFI-20 2 
+ 
Limited 
+ 
Limited 
? 
Unknown 
? 
Unknown 
 ES, SRM, Guyatt  
MFSI-SF 1   
? 
Unknown 
? 
Unknown 
   
Unidimensional fatigue measures (2/9) 
FACIT-fatigue 2 
? 
Unknown 
 
+ 
Moderate 
 
? 
Unknown 
  
FSS 3   
? 
Unknown 
? 
Unknown 
 ES, SRM  
Single-item fatigue measures (3/9)  
BFI WF NRS 1 Review of practical properties only 
10cm VAS (BASDAI) 18  
- 
Limited 
+ 
Moderate 
? 
Unknown 
+ 
Limited 
ES, SRM, Guyatt 
? 
Unknown 
Modified 10cm VAS 1       
? 
Unknown 
Fatigue-specific PROM subscale (1/9) 
SF-36  
(vitality domain) 
10 
+ 
Moderate 
 
+ 
Limited 
? 
Unknown 
 ES, SRM  
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 b Overall quality: There was no measurement evidence available for the following measurement properties and they are therefore not referred to in the synthesis table: measurement error, content validity and structural validity. 
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